Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Xilio Reports $10.0 Million Third-Quarter Revenue and $5.9 Million Net Loss

None

Xilio Therapeutics (XLO) reported third-quarter 2026 collaboration and license revenue of $10.0 million and a net loss of $5.9 million, or $0.30 per basic and diluted share. Cash and cash equivalents totaled $122.2 million at September 30, 2026.

The company dosed the first patient in its Phase 1/2 trial of XTX501 for metastatic non-small cell lung cancer and select advanced solid tumors. Xilio plans to report initial Phase 1 data for metastatic NSCLC in the fourth quarter of 2027.

  • Third-quarter collaboration and license revenue was $10.0 million, compared with $19.1 million a year earlier.
  • R&D expense was $14.8 million, while G&A expense was $6.9 million.
  • Xilio plans fourth-quarter 2027 IND submissions for XTX602 and XTX701.
  • The company expects existing cash and cash equivalents to fund operations into the first quarter of 2028.
EARLY ACCESS
Receive XLO Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$XLO Hedge Fund Activity

We have seen 13 institutional investors add shares of $XLO stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles